The city of Augusta, Georgia, currently has 3 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
02/18/2025
Locations: Masters of Clinical Research, Augusta, Georgia
Conditions: Alzheimer Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: Local Institution - 1152, Augusta, Georgia
Conditions: Psychosis Associated With Alzheimer's Disease
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Recruiting
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
10/02/2024
Locations: Georgia Memory Net Memory Assessment Clinic - Augusta, Augusta, Georgia
Conditions: Alzheimer Disease